Tags

Type your tag names separated by a space and hit enter

African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans.
Am J Cardiol. 2007 Mar 26; 99(6B):3D-6D.AJ

Abstract

Heart failure (HF) in African Americans may have differences in etiology and drug response. Compared with coronary disease in whites, HF in African Americans is marked by increased prevalence, earlier onset, increased risk for hospitalization and mortality, and increased prevalence of hypertension as the underlying cause of disease. There are apparent differences in pathophysiology and response to cardiac drugs. Endothelial dysfunction is potentially among the hallmarks of HF in this population, with diminished release of nitric oxygen (NO), increased inactivation of NO caused by increased oxidant stress, and impaired antioxidant defenses. Novel approaches to HF in African Americans include the use of isosorbide dinitrate combined with hydralazine in a fixed-dose formulation, which may affect endothelial dysfunction and the relative contribution of NO deficiency in this population. The African American Heart Failure Trial (A-HeFT) demonstrated improvement in morbidity and mortality, including a 39% reduction in hospitalization, improvement in quality of life or functional status, and a 43% reduction in mortality. When added to standard therapy, isosorbide dinitrate and hydralazine provide an evidence-based approach to diminishing morbidity and mortality in this high-risk population.

Authors+Show Affiliations

Division of Cardiology and the Clinical Research Center, Morehouse School of Medicine, Atlanta, Georgia 30310, USA. kferdinand@abcardio.org

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17378993

Citation

Ferdinand, Keith C.. "African American Heart Failure Trial: Role of Endothelial Dysfunction and Heart Failure in African Americans." The American Journal of Cardiology, vol. 99, no. 6B, 2007, 3D-6D.
Ferdinand KC. African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. Am J Cardiol. 2007;99(6B):3D-6D.
Ferdinand, K. C. (2007). African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. The American Journal of Cardiology, 99(6B), 3D-6D.
Ferdinand KC. African American Heart Failure Trial: Role of Endothelial Dysfunction and Heart Failure in African Americans. Am J Cardiol. 2007 Mar 26;99(6B):3D-6D. PubMed PMID: 17378993.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. A1 - Ferdinand,Keith C, Y1 - 2007/01/25/ PY - 2007/3/24/pubmed PY - 2007/5/4/medline PY - 2007/3/24/entrez SP - 3D EP - 6D JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 99 IS - 6B N2 - Heart failure (HF) in African Americans may have differences in etiology and drug response. Compared with coronary disease in whites, HF in African Americans is marked by increased prevalence, earlier onset, increased risk for hospitalization and mortality, and increased prevalence of hypertension as the underlying cause of disease. There are apparent differences in pathophysiology and response to cardiac drugs. Endothelial dysfunction is potentially among the hallmarks of HF in this population, with diminished release of nitric oxygen (NO), increased inactivation of NO caused by increased oxidant stress, and impaired antioxidant defenses. Novel approaches to HF in African Americans include the use of isosorbide dinitrate combined with hydralazine in a fixed-dose formulation, which may affect endothelial dysfunction and the relative contribution of NO deficiency in this population. The African American Heart Failure Trial (A-HeFT) demonstrated improvement in morbidity and mortality, including a 39% reduction in hospitalization, improvement in quality of life or functional status, and a 43% reduction in mortality. When added to standard therapy, isosorbide dinitrate and hydralazine provide an evidence-based approach to diminishing morbidity and mortality in this high-risk population. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/17378993/African_American_heart_failure_trial:_role_of_endothelial_dysfunction_and_heart_failure_in_African_Americans_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(06)02477-5 DB - PRIME DP - Unbound Medicine ER -